The bioadaptor device supports the healing vessel in patients with CLTI. Credit: edwardolive/Shutterstock.com.

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Elixir Medical’s DynamX BTK System.

The adaptive implant is designed for the treatment of narrowed or blocked vessels below the knee (BTK) in individuals with chronic limb-threatening ischemia (CLTI), a severe condition that can lead to amputation if left untreated.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Elixir’s DynamX BTK System broadens the application of its bioadaptor platform technology, which was initially developed for coronary artery disease.

The DynamX Bioadaptor platform represents a significant advancement in vascular interventions, potentially setting a new standard of care.

This platform is a metallic device that supports the healing vessel and then ‘uncages’ to allow for vessel movement and function, aiming to maintain an open lumen and improve blood flow.

See Also:

Clinical data has demonstrated that the DynamX Bioadaptor can restore vessel motion and function, including increased blood flow volume and positive adaptive remodelling.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Elixir Medical CEO Motasim Sirhan said: “The Bioadaptor platform was developed to transform the treatment of coronary and peripheral artery disease.

“We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease.”

Currently, the DynamX BTK System is not available for sale in the US, but the FDA’s breakthrough device designation could expedite its development and review process.

In July 2023, Elixir Medical said the final patient was enrolled in a study comparing its metallic coronary artery implant to Resolute Onyx’s drug-eluting stent (DES).

The multicentre, prospective, single-blind, randomised registry-based trial enrolled 2,400 patients with ischemic heart disease across Sweden with a primary endpoint of target lesion failure at a one-year follow-up.